

BIOSCIENCE INITIATIVE

The 2004 Kansas Legislature created the Kansas Economic Growth Act to foster the growth of bioscience businesses in Kansas, to make Kansas a national leader in bioscience, and to make Kansas a desirable location for bioscience entities to locate and grow.

Bioscience is defined in K.S.A. 74-99b33(c) as, “the use of compositions, methods and organisms in cellular and molecular research, development and manufacturing processes for such diverse areas as pharmaceuticals, medical therapeutics, medical diagnostics, medical devices, medical instruments, biochemistry, microbiology, veterinary medicine, plant biology, agriculture, industrial, environmental, and homeland security applications of bioscience and future developments in the biosciences. Bioscience includes biotechnology and life sciences.”

Biotechnology means those fields focusing on technological developments in such areas as molecular biology, genetic engineering, genomics, proteomics, physiomics, nanotechnology, biodefense, biocomputing and bioinformatics and future developments associated with biotechnology. (K.S.A. 74-99b33(h))

Life sciences means without limitation, the areas of medical sciences, pharmaceutical sciences, biological sciences, zoology, botany, horticulture, ecology, toxicology, organic chemistry, physical chemistry and physiology and any future advances associated with the life sciences. (K.S.A. 74-99b33(k))

This bioscience initiative is funded by 95% of the current year Kansas withholding taxes in excess of 95% of the base year taxation (2003) from all bioscience companies and employees employed by state universities associated with bioscience research.

Kansas Bioscience Companies

The Emerging Industry Investment Act (K.S.A. 74-99b33(d)) has defined bioscience company as follows: “a corporation, limited liability company, S corporation, partnership, registered limited liability partnership, foundation, association, nonprofit entity, sole proprietorship, business trust, person, group or other entity that is engaged in the business of bioscience in the state and has business operations in the state, including, without limitation, research, development, sales, services, distribution or production directed towards developing or providing bioscience products or processes for specific commercial or public purposes but shall not include entities engaged in the distribution or retail sale of pharmaceuticals or other bioscience products. The authority and the secretary of revenue shall jointly determine whether an entity qualifies as a “bioscience company” based on verifiable evidence. One of the factors that shall be considered is whether a company has been identified by the department of labor by one of the following NAICS codes: 325411, 325412, 325413, 325414, 325193, 325199, 325311, 325320, 334516, 339111, 339112, 339113, 334510, 334517, 339115, 621511, 621512, 541710, 541380, 541940 and 622110. Such company shall be presumed to be a bioscience company unless the authority and the secretary of revenue agree, based on verifiable evidence, that the company is not engaged in the business of bioscience in the state. A company identified by another NAICS code may be determined to be a bioscience company by the authority and the secretary of revenue based on verifiable evidence that the company is engaged in the business of bioscience in the state.”

Kansas State Universities

The Emerging Industry Investment Act (K.S.A. 74-99b33(o)) has defined state universities as, “state educational institutions as defined in K.S.A. 76-711, and amendments thereto, and the municipal university as defined in K.S.A. 74-3201b, and amendments thereto.”

State educational institution means the university of Kansas, Kansas state university of agriculture and applied science, Wichita state university, Emporia state university, Pittsburg state university, and Fort Hays state university.” (K.S.A. 76-711(a))

Municipal university means Washburn university of Topeka or any other municipal university established under the law of this state. (K.S.A. 74-3201b(c))

The Kansas Department of Revenue and the Kansas Bioscience Authority have worked closely to determine the Kansas bioscience companies. Should a company be registered with the Kansas Department of Revenue with one of the appropriate NAICS codes as provided in K.S.A. 74-99b33(d), such company shall be presumed to be a “bioscience company”, and all Kansas withholding for employees employed by this bioscience company shall be included as bioscience data. It is assumed that the company has reported the NAICS to KDOR as is on file with the Department of Labor.

A company identified by another NAICS code may be determined to be a “bioscience company” by the Kansas Bioscience Authority and the Secretary of Revenue based on verifiable evidence that the company is engaged in the business of bioscience in the state. These companies have been identified under the “other” category.

K.S.A. 74-99b34 allows the state treasurer to make estimated payments to the Kansas Bioscience Authority. The Department of Revenue computes the quarterly estimated payments based on withholding deposit reports submitted to the Department by bioscience companies within a quarterly period. Withholding from the Kansas state universities is computed on an annual basis. Reconciliations are prepared periodically.

In 2016 the Kansas Legislature passed House Bill No. 2632 which authorizes the State Finance Council to oversee the sale of the Kansas Bioscience Authority or substantially all of its assets.

Bioscience Distributions

Calendar Year 2004 compared to Base Year of 2003		Distribution	Date of Distribution
Bioscience Companies (2004-2003)		\$5,367,713.67	7/1/2005
Reconciliation Bioscience Companies		\$114,976.62	11/6/2006
Reconciliation Bioscience Companies		\$982,772.54	2/5/2010
State Universities		\$625,004.71	7/1/2005
*Reconciliation State Universities		\$10,036.18	5/25/2011
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$10,036.18 for state universities.		\$10,036.18	
Calendar Year 2004		\$7,090,467.54	
Calendar Year 2005 compared to Base Year of 2003			
Bioscience Companies (Jan-Jun)		\$3,297,482.97	1/27/2006
Bioscience Companies (Jul-Dec)		\$7,099,067.28	4/5/2006
Reconciliation Bioscience Companies		\$1,576,647.80	11/6/2006
Reconciliation Bioscience Companies		\$1,220,100.66	2/5/2010
State Universities		\$886,784.88	8/2/2006
*Reconciliation State Universities		\$24,336.12	5/25/2011
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$24,336.12 for state universities.		\$24,336.12	
Calendar Year 2005		\$14,080,083.59	
Calendar Year 2006 compared to Base Year of 2003			
Bioscience Companies (Jan-Mar)		\$3,584,708.68	5/15/2006
Bioscience Companies (Apr-Jun)		\$3,860,852.87	8/2/2006
Bioscience Companies (Jul-Sep)		\$4,556,097.14	11/6/2006
Bioscience Companies (Oct-Dec)		\$5,658,229.96	2/6/2007
Reconciliation Bioscience Companies		\$1,785,439.73	2/7/2008
Reconciliation Bioscience Companies		\$2,222,777.45	2/5/2010
State Universities		\$1,471,486.09	5/7/2007
*Reconciliation State Universities		\$36,753.33	5/25/2011
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$36,753.33 for state universities.		\$36,753.33	
Calendar Year 2006		\$23,139,591.92	

Bioscience Distributions

Calendar Year 2007 compared to Base Year of 2003			
Bioscience Companies (Jan-Mar)		\$6,389,896.69	5/7/2007
Bioscience Companies (Apr-Jun)		\$6,355,061.73	8/7/2007
Bioscience Companies (Jul-Sep)		\$7,166,172.47	11/7/2007
Bioscience Companies (Oct-Dec)		\$9,553,995.75	2/7/2008
Reconciliation Bioscience Companies		\$3,538,899.36	2/5/2010
State Universities		\$2,130,213.45	5/7/2008
*Reconciliation State Universities		-\$6,237.91	5/25/2011
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$-6,237.91 for state universities.		-\$6,237.91	
Calendar Year 2007		\$35,134,239.45	
Calendar Year 2008 compared to Base Year of 2003			
Bioscience Companies (Jan-Mar)		\$8,900,794.46	5/7/2008
Bioscience Companies (Apr-Jun)		\$8,870,561.28	8/7/2008
Bioscience Companies (Jul-Sep)		\$9,520,781.72	11/4/2008
Bioscience Companies (Oct-Dec)		\$12,157,789.54	2/6/2009
Reconciliation Bioscience Companies		\$4,719,839.71	11/8/2010
State Universities		\$2,323,608.06	5/7/2009
*Reconciliation State Universities		\$507,966.57	5/25/2011
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$507,966.57 for state universities.		\$507,966.57	
Calendar Year 2008		\$46,493,374.77	
Calendar Year 2009 compared to Base Year of 2003			
*Bioscience Companies (Jan-Mar)		\$8,686,115.88	5/7/2009
Bioscience Companies (Apr-Jun)		\$8,655,796.80	8/11/2009
Bioscience Companies (Jul-Sep)		\$8,589,498.34	11/6/2009
*Bioscience Companies (Oct-Dec)		\$11,771,741.40	2/5/2010
*Reconciliation Bioscience Companies		\$14,832,216.49	11/7/2011
*State Universities		\$3,250,430.82	5/10/2010
*Reconciliation State Universities		-\$211,512.00	5/25/2011
*Distribution for 05/07/09 was reduced to meet FY 09 transfer limitation of \$35M. Total distribution for 05/07/09, \$11,009,723.94 was reduced by \$6,558,856.48, with actual distribution of \$4,450,867.46. Reduction includes \$6,558,856.48 for bioscience companies.		\$6,558,856.48	

Bioscience Distributions

*Distribution for 02/05/2010 was reduced to meet FY 10 transfer limitation of \$35M. Total distribution for 02/05/2010, \$19,736,291.41 was reduced by \$1,981,586.55 with actual distribution of \$17,754,704.86. Reduction includes \$1,981,586.55 for bioscience companies.				\$1,981,586.55	
*Distribution for 05/10/2010 was reduced to meet FY 10 transfer limitation of \$35M. Total distribution for 05/10/2010, \$12,297,951.07 was reduced by \$12,297,951.07 with actual distribution of \$0. Reduction includes \$3,250,430.82 for state universities.				\$3,250,430.82	
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$-211,512.00 for state universities.				-\$211,512.00	
*Distribution for 11/7/2011 was reduced due to 2011 Senate Substitute for House Bill 2014, Section 191 to meet the FY 12 transfer limitation of \$35M which shall take into consideration the \$1,000,000 transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University. Distribution for 11/7/2011 included the third quarter for 2011, \$14,182,971.55 and the reconciliation for 2009, \$14,832,216.49.				\$14,832,216.49	
*2012 House Substitute for Senate Bill 294, Section 156(i) passed in May 2012 limits the aggregate amount to be transferred from the state general fund to the bioscience development and investment fund to \$12,322,186 (which includes the \$1,000,000 transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University) for the fiscal year ending June 30, 2012. Therefore this distribution was not made.					
Calendar Year 2009				\$29,162,709.39	
Calendar Year 2010 compared to Base Year of 2003					
*Bioscience Companies (Jan-Mar)				\$9,047,520.25	5/10/2010
Bioscience Companies (Apr-Jun)				\$9,729,682.53	8/9/2010
Bioscience Companies (Jul-Sep)				\$10,243,231.47	11/8/2010
*Bioscience Companies (Oct-Dec)				\$13,793,102.23	2/7/2011
*Reconciliation Bioscience Companies				\$14,696,398.10	11/13/2012
*State Universities				\$3,029,591.43	5/25/2011
*Distribution for 05/10/2010 was reduced to meet FY 10 transfer limitation of \$35M. Total distribution for 05/10/2010, \$12,297,951.07 was reduced by \$12,297,951.07 with actual distribution of \$0. Reduction includes \$9,047,520.25 for bioscience companies.				\$9,047,520.25	

Bioscience Distributions

*Distribution for 02/07/11 was reduced to meet FY 11 transfer limitation of \$35M. Total distribution for 02/07/11, \$13,793,102.23 was reduced by \$3,485,855.94, with actual distribution of \$10,307,246.29.					
					\$3,485,855.94
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$3,029,591.43 for state universities.					
					\$3,029,591.43
*Distribution for 11/13/12 was reduced due to 2012 House Substitute for Senate Bill 294 (section 191) transfer to meet FY 13 limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University. Total distribution for 11/13/12, \$29,457,505.54 was reduced by \$6,744,772.26, with actual distribution of \$22,712,733.28.					
*Distribution for 11/13/12 was not made due to 2013 Senate Bill 171, Section 268 which provides that the amount distributed for FY 13 shall not exceed \$12,287,267. Therefore the first distribution in FY 2013 was the only one made.					
					\$14,696,398.10
					\$30,280,160.29
Calendar Year 2010					
Calendar Year 2011 compared to Base Year of 2003					
*Bioscience Companies (Jan-Mar)				\$11,007,856.40	5/25/2011
*Bioscience Companies (Apr-Jun)				\$12,322,185.51	8/12/2011
*Bioscience Companies (Jul-Sep)				\$14,182,971.55	11/7/2011
*Bioscience Companies (Oct-Dec)				\$12,917,909.99	2/7/2012
*Reconciliation Bioscience Companies				\$15,443,702.92	11/6/2013
*State Universities				\$3,357,741.68	5/7/2012
*Distribution for 05/25/2011 was not made due to the SFY 11 cap limitation of \$35M. Total distribution for 05/25/2011, \$14,398,790.12 was reduced by \$14,398,790.12, with actual distribution of \$0. Reduction includes \$11,007,856.40 for state universities.					
					\$11,007,856.40
*Distribution for 08/12/11 was reduced due to 2011 House Bill 1044 (section 191) instructing for FY 2012, the first \$1,000,000 shall be transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University. Total distribution for 08/12/11, \$12,322,185.51 was reduced by \$1,000,000, with actual distribution of \$11,322,185.51.					
					\$1,000,000.00

Bioscience Distributions

*Distribution for 11/7/11 was reduced due to 2011 House Bill 2014 (section 191) to meet FY 12 transfer limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University. Total distribution for 11/7/11, \$29,015,188.04 was reduced by \$6,337,373.55, with actual distribution of \$22,677,814.49. Reduction includes \$6,337.373.55 for bioscience companies.					\$6,337,373.55
*2012 House Substitute for Senate Bill 294, Section 156(i) passed in May 2012 limits the aggregate amount to be transferred from the state general fund to the bioscience development and investment fund to \$12,322,186 (which includes the \$1,000,000 transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University) for the fiscal year ending June 30, 2012. Therefore this distribution was not made.					\$7,845,598.00
*Distribution for 2/7/12 was reduced due to 2011 House Bill 2014 (section 191) to meet FY 12 transfer limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University. Total distribution for 2/7/12, \$12,917,909.99 was reduced by \$12,917,909.99, with actual distribution of \$0. Reduction includes \$12,917,909.99 for bioscience companies.					\$12,917,909.99
*2012 House Substitute for Senate Bill 294, Section 156(i) passed in May 2012 limits the aggregate amount to be transferred from the state general fund to the bioscience development and investment fund to \$12,322,186 (which includes the \$1,000,000 transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University) for the fiscal year ending June 30, 2012.					
*Distribution for 05/07/2012 was reduced due to 2011 House Bill 2014 (section 191) to meet FY 12 transfer limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University. Total distribution for 05/07/2012, \$18,506,644.10 was reduced by \$18,506,644.10, with actual distribution of \$0. Reduction includes \$3,357,741.68 for state universities.					\$3,357,741.68
*2012 House Substitute for Senate Bill 294, Section 156(i) passed in May 2012 limits the aggregate amount to be transferred from the state general fund to the bioscience development and investment fund to \$12,322,186 (which includes the \$1,000,000 transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-					

Bioscience Distributions

Wichita State University) for the fiscal year ending June 30, 2012.					
*Distribution for 11/6/13 was reduced due to 2013 Senate Bill 171 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$10M for the fiscal year ending June 30, 2014 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A)) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A)). Total distribution for 11/6/13, \$23,947,780.99 was reduced by \$20,713,964.44, with actual distribution of \$3,233,816.55.					
Reduction includes \$12,209,886.37 for the 2011 reconciliation and \$8,504,078.07 for bioscience companies.				\$12,209,886.37	
Calendar Year 2011				\$14,556,002.06	
Calendar Year 2012 compared to Base Year of 2003					
*Bioscience Companies (Jan-Mar)				\$15,148,902.42	5/7/2012
*Bioscience Companies (Apr-Jun)				\$12,287,266.72	8/8/2012
*Bioscience Companies (Jul-Sep)				\$14,761,107.44	11/13/2012
*Bioscience Companies (Oct-Dec)				\$15,649,275.34	2/8/2013
*Reconciliation Bioscience Companies				\$16,383,941.40	11/12/2014
*State Universities				\$3,817,911.48	5/10/2013
*Distribution for 05/07/2012 was reduced due to 2011 House Bill 2014 (section 191) to meet FY 12 transfer limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research- Wichita State University. Total distribution for 05/07/2012, \$18,506,644.10 was reduced by \$18,506,644.10, with actual distribution of \$0.					
Reduction includes \$15,148,902.42 for state universities.				\$15,148,902.42	
*2012 House Substitute for Senate Bill 294, Section 156(i) passed in May 2012 limits the aggregate amount to be transferred from the state general fund to the bioscience development and investment fund to \$12,322,186 (which includes the \$1,000,000 transferred to the Center of Innovation for Biomaterials in Orthopaedic Research- Wichita State University) for the fiscal year ending June 30, 2012.					
*Distribution for 8/8/12 was reduced due to 2012 House Substitute for Senate Bill 294 (section 156) which instructs for FY 2013 the first \$1M shall be transferred to the Center of Innovation for Biomaterials in Orthopaedic					

Bioscience Distributions

Research-Wichita State University.				\$1,000,000.00	
*Distribution for 8/8/12 was reduced due to 2012 House Substitute for Senate Bill 294 (section 156) which instructs for FY 2013 the next \$5M shall be transferred to the National Bio Agro-Defense Facility Fund at Kansas State University.					
				\$5,000,000.00	
*Distribution for 11/13/12 was reduced due to 2012 House Substitute for Senate Bill 294 (section 191) to meet FY 13 limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University. Total distribution for 11/13/12, \$29,457,505.54 was reduced by \$6,744,772.26, with actual distribution of \$22,712,733.28. To date (1/24/2013) this distribution has not been made.					
				\$6,744,772.26	
*Distribution for 11/13/12 was not made due to 2013 Senate Bill 171, Section 268 which provides that the amount distributed for FY 13 shall not exceed \$12,287,267. Therefore the first distribution in FY 2013 was the only one made.					
				\$8,016,335.18	
*Distribution for 02/8/13 was reduced due to 2012 House Substitute for Senate Bill 294 to meet FY 13 transfer limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University and the transfer of \$5M to the National Bio Agro-Defense Facility Fund at Kansas State University. Total distribution for 2/8/13, \$15,649,275.34 was reduced by \$15,649,275.34, with actual distribution of \$0.					
				\$15,649,275.34	
*Distribution for 2/8/13 was not made due to 2013 Senate Bill 171, Section 268 which provides that the amount distributed for FY 13 shall not exceed \$12,287,267. Therefore the first distribution in FY 2013 was the only one made.					
*Distribution for 5/10/13 was reduced due to 2012 House Substitute for Senate Bill 294 to meet FY 13 transfer limitation of \$35M which shall take into consideration the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University and the transfer of \$5M to the National Bio Agro-Defense Facility Fund at Kansas State University. Total distribution for 5/10/13, \$13,495,166.37 was reduced by \$13,495,166.37, with actual distribution of \$0. Reduction includes \$9,677,254.89 for bioscience companies and \$3,817,911.48 for state universities.					
				\$3,817,911.48	
*Distribution for 5/10/13 was not made due to 2013 Senate Bill 171, Section 268 which provides that the amount					

Bioscience Distributions

distributed for FY 13 shall not exceed \$12,287,267.					
Therefore the first distribution in FY 2013 was the only					
one made.					
*Distribution for 11/12/14 was not made. Distribution					
included \$7,919,641.97 for bioscience companies and					
\$16,383,941.40 for the 2012 reconciliation.				\$16,383,941.40	
Calendar Year 2012				\$6,287,266.72	
Calendar Year 2013 compared to Base Year of 2003					
*Bioscience Companies (Jan-Mar)				\$9,677,254.89	5/10/2013
*Bioscience Companies (Apr-Jun)				\$6,766,183.45	8/7/2013
*Bioscience Companies (Jul-Sep)				\$8,504,078.07	11/6/2013
*Bioscience Companies (Oct-Dec)				\$8,306,708.99	2/7/2014
*Reconciliation Bioscience Companies				\$12,977,695.68	11/9/2015
*State Universities				\$1,884,705.64	5/21/2014
*Distribution for 5/10/13 was reduced due to 2012 House					
Substitute for Senate Bill 294 to meet FY 13 transfer					
limitation of \$35M which shall take into consideration the					
\$1M transfer made to the Center of Innovation for					
Biomaterials in Orthopaedic Research-Wichita State					
University and the transfer of \$5M to the National Bio					
Agro-Defense Facility Fund at Kansas State University.					
Total distribution for 5/10/13, \$13,495,166.37 was					
reduced by \$13,495,166.37, with actual distribution of \$0.					
Reduction includes \$9,677,254.89 for bioscience					
companies and \$3,817,911.48 for state universities.				\$9,677,254.89	
*Distribution for 5/10/13 was not made due to 2013 Senate					
Bill 171, Section 268 which provides that the amount					
distributed for FY 13 shall not exceed \$12,287,267.					
Therefore the first distribution in FY 2013 was the only					
one made.					
*Distribution for 8/7/13 was reduced due to 2013 Senate					
Bill 171 (section 268) which instructs for FY 2014					
the first \$1M shall be transferred					
to the Center of Innovation for Biomaterials in Orthopaedic					
Research-Wichita State University.				\$1,000,000.00	
*Distribution for 8/7/13 was reduced due to 2013 Senate					
Bill 171 (section 268) which instructs for FY 2014					
the next \$5M shall be transferred to					
the National Bio Agro-Defense Facility Fund at Kansas					
State University.				\$5,000,000.00	
*Distribution for 11/6/13 was reduced due to 2013 Senate					
Bill 171 which limits the aggregate amount that is directed					
to be transferred from the state general fund to the					
bioscience development and investment fund to \$10M for					
the fiscal year ending June 30, 2014 which includes the					

Bioscience Distributions

\$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A)) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A)). Total distribution for 11/6/13, \$23,947,780.99 was reduced by \$20,713,964.44, with actual distribution of \$3,233,816.55.		
Reduction includes \$12,209,886.37 for the 2011 reconciliation and \$8,504,078.07 for bioscience companies.	\$8,504,078.07	
*Distribution for 2/7/14 was reduced due to 2013 Senate Bill 171 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$10M for the fiscal year ending June 30, 2014 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A)) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A)). Total distribution for 2/7/14, \$8,306,708.99 was reduced by \$8,306,708.99, with actual distribution of \$0.		
Reduction includes \$8,306,708.99 for bioscience companies.	\$8,306,708.99	
*Distribution for 5/21/2014 was reduced due to 2013 Senate Bill 171 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$10M for the fiscal year ending June 30, 2014 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A)) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A)). Total distribution for 5/21/14, \$10,661,804.59 was reduced by \$10,661,804.59, with actual distribution of \$0.		
Reduction includes \$1,884,705.64 for state universities.	\$1,884,705.64	
*Distribution for 11/9/2015 was not made. Distribution included \$8,693,074.96 for bioscience companies and \$12,977,695.68 for the 2013 reconciliation.	\$12,977,695.68	
Calendar Year 2013 (to date)	\$766,183.45	
Calendar Year 2014 compared to Base Year of 2003		
*Bioscience Companies (Jan-Mar)	\$8,777,098.95	5/21/2014
*Bioscience Companies (Apr-Jun)	\$7,681,889.45	8/13/2014
*Bioscience Companies (Jul-Sep)	\$7,919,641.97	11/12/2014

Bioscience Distributions

*Bioscience Companies (Oct-Dec)				\$7,970,717.53	2/9/2015
*State Universities				\$2,238,957.12	6/25/2015
*Distribution for 5/21/2014 was reduced due to 2013 Senate Bill 171 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$10M for the fiscal year ending June 30, 2014 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A)) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A)). Total distribution for 5/21/14, \$10,661,804.59 was reduced by \$10,661,804.59, with actual distribution of \$0. Reduction includes \$8,777,098.95 for bioscience companies.					
				\$8,777,098.95	
*Distribution for 8/13/14 was reduced due to 2013 Senate Bill 171 (section 268) which instructs for FY 2015 the first \$1M shall be transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University.					
				\$1,000,000.00	
*Distribution for 8/13/14 was reduced due to 2013 Senate Bill 171 (section 268) which instructs for FY 2015 the next \$5M shall be transferred to the National Bio Agro-Defense Facility Fund at Kansas State University.					
				\$5,000,000.00	
*Distribution for 11/12/14 was not made. Distribution included \$7,919,641.97 for bioscience companies and \$16,383,941.40 for the 2012 reconciliation.					
				\$7,919,641.97	
*Distribution for 2/9/15 was reduced due to 2014 Senate Substitute for Substitute for House Bill 2231 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$32M for the fiscal year 2015 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A)) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A)). Total distribution for 2/7/14, \$7,970,717.53 was reduced by \$7,956,190.35, with actual distribution of \$14,527.18. Reduction includes \$7,970,717.53 for bioscience companies. This distribution was not made.					
				\$7,970,717.53	
*Distribution for 6/25/15 was reduced due to 2015 House Substitute for Senate Bill 112 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$13M for the fiscal year ending					

Bioscience Distributions

June 30, 2015 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A), 2013 Senate Bill 171) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A), 2013 Senate Bill 171).					
Total distribution for 6/25/15, \$11,514,842.52 was reduced by \$6,196,731.97, with actual distribution of \$5,318,110.55. Reduction includes \$2,238,957.12 for state universities and \$3,957,774.85 for bioscience companies.					
				\$2,238,957.12	
Calendar Year 2014 (to date)				\$1,681,889.45	
Calendar Year 2015 compared to Base Year of 2003					
*Bioscience Companies (Jan-Mar)				\$9,275,885.40	6/25/2015
*Bioscience Companies (Apr-Jun)				\$6,997,663.24	8/21/2015
*Bioscience Companies (Jul-Sep)				\$8,693,074.96	11/9/2015
*Bioscience Companies (Oct-Dec)				\$11,439,596.17	2/15/2016
*State Universities					
*Distribution for 6/25/15 was reduced due to 2015 House Substitute for Senate Bill 112 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$13M for the fiscal year ending June 30, 2015 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 268(d)(2)(A), 2013 Senate Bill 171) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 268(d)(3)(A), 2013 Senate Bill 171). Total distribution for 6/25/15, \$11,514,842.52 was reduced by \$6,196,731.97, with actual distribution of \$5,318,110.55. Reduction includes \$2,238,957.12 for state universities and \$3,957,774.85 for bioscience companies.					
				\$3,957,774.85	
*Distribution for 8/21/15 was reduced due to 2015 House Substitute for Senate Bill 112 (section 239) which instructs for FY 2016 the first \$1M shall be transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University.					
				\$1,000,000.00	
*Distribution for 8/21/15 was reduced due to 2015 House Substitute for Senate Bill 112 (section 239) which instructs for FY 2016 the next \$5M shall be transferred to the National Bio Agro-Defense Facility Fund at Kansas State University.					
				\$5,000,000.00	
*Distribution for 11/9/2015 was not made. Distribution included \$8,693,074.96 for bioscience companies and					

Bioscience Distributions

\$12,977,695.68 for the 2013 reconciliation.		\$8,693,074.96	
*Distribution for 2/15/16 was reduced due to 2016 House Substitute for Senate Bill 249 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$6,997,663 for the fiscal year ending June 30, 2016 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 239(d)(2)(A), 2015 House Substitute for Senate Bill 112) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 239(d)(3)(A), 2015 House Substitute for Senate Bill 112). Total distribution for 2/15/16, \$11,439,596.17 was reduced by \$11,439,596.17, with actual distribution of \$0.			
		\$11,439,596.17	
Calendar Year 2015 (to date)		\$6,315,773.79	
Calendar Year 2016 compared to Base Year of 2003			
*Bioscience Companies (Jan-Mar)		\$0.00	
*Bioscience Companies (Apr-Jun)		\$6,960,277.02	8/22/2016
*Bioscience Companies (Jul-Sep)			
*Bioscience Companies (Oct-Dec)			
*State Universities			
*No distribution was made in May 2016.			
*Distribution for 8/22/16 was reduced due to 2015 House Substitute for Senate Bill 112 (section 239) which instructs for FY 2017 the first \$1M shall be transferred to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University.			
		\$1,000,000.00	
*Distribution for 8/22/16 was reduced due to 2015 House Substitute for Senate Bill 112 (section 239) which instructs for FY 2017 the next \$5M shall be transferred to the National Bio Agro-Defense Facility Fund at Kansas State University.			
		\$5,000,000.00	
*Distribution for 8/22/16 was reduced due to 2016 House Substitute for Senate Bill 161 which limits the aggregate amount that is directed to be transferred from the state general fund to the bioscience development and investment fund to \$6M for the fiscal year ending June 30, 2017 which includes the \$1M transfer made to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University (Section 239(d)(2)(A), 2015 House Substitute for Senate Bill 112) and the \$5M transfer made to the National Bio Agro-Defense Facility Fund at Kansas State University (Section 239(d)(3)(A), 2015 House Substitute for Senate Bill 112). Total distribution for 8/22/16, \$960,277.02 was reduced by			

Bioscience Distributions

\$960,277.02, with actual distribution of \$0.		\$960,277.02	
Calendar Year 2016 (to date)		\$0.00	
Total Distributions to Kansas Bioscience Authority		\$214,987,742.42	
Total Transfers to the Center of Innovation for Biomaterials in Orthopaedic Research-Wichita State University		\$1,000,000.00	FY 2012
		\$1,000,000.00	FY 2013
		\$1,000,000.00	FY 2014
		\$1,000,000.00	FY 2015
		\$1,000,000.00	FY 2016
		\$1,000,000.00	FY 2017
Total Transfers to the National Bio Agro-Defense Facility Fund at Kansas State University		\$5,000,000.00	FY 2013
		\$5,000,000.00	FY 2014
		\$5,000,000.00	FY 2015
		\$5,000,000.00	FY 2016
		\$5,000,000.00	FY 2017